AAAAI 2022: Dupilumab Use Safe for Up To 172 Weeks in Adult Patients With Atopic Dermatitis
Conjunctivitis rates were lower than the active therapy arm in the CHRONOS trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.